Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $9 from $10 and keeps an Outperform rating on the shares. The firm is adjusting its model after the company’s Q1 results and updates on its cash and share position, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRV:
- Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer
- Acrivon Therapeutics reports Q1 EPS (51c), consensus (65c)
- Acrivon Therapeutics sees cash, equivalents funding expenses into 2Q27
- Acrivon Therapeutics assumed with an Overweight at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today